Gemma Fowler
Overview
Explore the profile of Gemma Fowler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
1862
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Seed G, Beije N, Yuan W, Bertan C, Goodall J, Lundberg A, et al.
Cancer Cell
. 2024 Nov;
42(12):2113-2123.e4.
PMID: 39577422
PARP inhibition (PARPi) has anti-tumor activity against castration-resistant prostate cancer (CRPC) with homologous recombination repair (HRR) defects. However, mechanisms underlying PARPi resistance are not fully understood. While acquired mutations restoring...
2.
Scott E, Hodgson K, Calle B, Turner H, Cheung K, Bermudez A, et al.
Oncogene
. 2023 Feb;
42(12):926-937.
PMID: 36725887
Prostate cancer is the most common cancer in men and it is estimated that over 350,000 men worldwide die of prostate cancer every year. There remains an unmet clinical need...
3.
Gil V, Miranda S, Riisnaes R, Gurel B, DAmbrosio M, Vasciaveo A, et al.
Cancer Res
. 2021 Nov;
81(24):6207-6218.
PMID: 34753775
It has been recognized for decades that ERBB signaling is important in prostate cancer, but targeting ERBB receptors as a therapeutic strategy for prostate cancer has been ineffective clinically. However,...
4.
Sumanasuriya S, Seed G, Parr H, Christova R, Pope L, Bertan C, et al.
Eur Urol
. 2021 Jun;
80(2):243-253.
PMID: 34103179
Background: Better blood tests to elucidate the behaviour of metastatic castration-resistant prostate cancer (mCRPC) are urgently needed to drive therapeutic decisions. Plasma cell-free DNA (cfDNA) comprises normal and circulating tumour...
5.
Mateo J, Porta N, Bianchini D, McGovern U, Elliott T, Jones R, et al.
Lancet Oncol
. 2019 Dec;
21(1):162-174.
PMID: 31806540
Background: Metastatic castration-resistant prostate cancer is enriched in DNA damage response (DDR) gene aberrations. The TOPARP-B trial aims to prospectively validate the association between DDR gene aberrations and response to...
6.
Sharp A, Welti J, Lambros M, Dolling D, Nava Rodrigues D, Pope L, et al.
Eur Urol
. 2019 May;
76(5):676-685.
PMID: 31036442
Background: Detection of androgen receptor splice variant-7 (AR-V7) mRNA in circulating tumour cells (CTCs) is associated with worse outcome in metastatic castration-resistant prostate cancer (mCRPC). However, studies rarely report comparisons...
7.
de Wit S, Manicone M, Rossi E, Lampignano R, Yang L, Zill B, et al.
Oncotarget
. 2018 Nov;
9(86):35705-35716.
PMID: 30479699
The presence of high expressing epithelial cell adhesion molecule (EpCAM) circulating tumor cells (CTC) enumerated by CellSearch in blood of cancer patients is strongly associated with poor prognosis. This raises...
8.
Lambros M, Seed G, Sumanasuriya S, Gil V, Crespo M, Fontes M, et al.
Clin Cancer Res
. 2018 Aug;
24(22):5635-5644.
PMID: 30093450
Circulating tumor cells (CTCs) have clinical relevance, but their study has been limited by their low frequency. We evaluated liquid biopsies by apheresis to increase CTC yield from patients suffering...
9.
Andree K, Mentink A, Zeune L, Terstappen L, Stoecklein N, Neves R, et al.
Int J Cancer
. 2018 Jul;
143(10):2584-2591.
PMID: 30006930
Frequently, the number of circulating tumor cells (CTC) isolated in 7.5 mL of blood is too small to reliably determine tumor heterogeneity and to be representative as a "liquid biopsy"....
10.
Nanou A, Coumans F, van Dalum G, Zeune L, Dolling D, Onstenk W, et al.
Oncotarget
. 2018 May;
9(27):19283-19293.
PMID: 29721202
Purpose: The presence of Circulating Tumor Cells (CTCs) in Castration-Resistant Prostate Cancer (CRPC) patients is associated with poor prognosis. In this study, we evaluated the association of clinical outcome in...